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Large numbers of apoptotic cells (ACs) are constantly being generated that must be phagocytized by neighboring cells or "professional" phagocytes such as macrophages and dendritic cells. 1 If they are not cleared ACs can undergo necrosis; at this stage they become proinflammatory and immunogenic, possibly leading to the development of autoimmune diseases like arthritis and systemic lupus erythematous. Thus, efficient clearance of ACs (efferocytosis) by professional phagocytes is essential for maintaining cellular homeostasis. Once guided to ACs by "find me" signals, phagocytes recognize ACs through their display of characteristic cell surface molecules, known as "eat me" signals. 1 The most common "eat me" signal is phosphatidylserine (PS), which when exposed on the outer leaflet of the plasma membrane signals to phagocytes to engulf the ACs. Multiple receptors for PS exist on phagocytic cells, although not necessarily simultaneously, including brain-specific angiogenesis inhibitor 1 (BAI1), Tyro3, Axl, and MerTK receptor tyrosine kinases (TAMs), Stabilin1/2, and T-cell immunoglobulin and mucin domain containing 1 and 4 (TIM1/4) (Fig. 1) .
1 Most recently, several reports have highlighted the emerging role of the CD300 receptors as a protein family involved in efferocytosis and regulation of the immune response. [2] [3] [4] [5] [6] The human CD300 and mouse Cd300 family are diverse groups of molecules including both activating and inhibitory receptors that are expressed mainly by myeloid cells. 2 Activating receptors, such as CD300C and Cd300lb, require association with adaptor proteins to gain signaling capacity (Fig. 1) . Inhibitory receptors, such as CD300A, harbor immune-receptor tyrosine-based inhibitory motifs (ITIMs) within their intracellular tail that regulate the signaling events elicited after ligand recognition. A unique family member, Cd300lf, contains both activating and inhibitory motifs (Fig. 1) .
Recent studies provide important insights into the mechanisms by which CD300 molecules recognize their cellular ligands and carry out their immune response-specific functions. For example, CD300A-dependent recognition of PS and phosphatidylethanolamine (PE) results in the inhibition of efferocytosis. Cd300lf was shown to bind PS, phosphatidylglycerol (PG), and ceramide, 3, 4, 8 with PS being the predominant physiological ligand. 4, 8 Importantly, Cd300lf can initiate positive or negative signaling events to regulate efferocytosis, and lack of Cd300lf expression has been associated with the exacerbation of allergic responses and the development of autoimmune diseases. 3, 4 Intriguingly, whether Cd300lf functions as an activating or inhibitory receptor probably depends on the signaling capability within a cell type; Cd300lf can promote efferocytosis by Cd300lf-overexpressing L929-fibroblasts whereas transfection of Cd300lf into J774 macrophages inhibits their phagocytic activity. 4 Cd300lb has been demonstrated to be an activating receptor that gains activation potential by association with the adaptor protein DAP12.
9,10 Antibody cross-linking of CD300LB and Cd300lb initiates the production and release of proinflammatory cytokines from mast cells, and promotes cell adhesion to the extracellular matrix. 9 However, the precise role of Cd300lb in regulating myeloid cell functions remains elusive, in part Yamanishi et al. 5 have identified the PS binding receptors TIM1 and TIM4 as endogenous ligands for Cd300lb, but not PS itself; however, the significance and specificity of these interactions were not clear. The most recent report by Murakami et al. 10 provides important insights into Cd300lb ligand identity and its downstream signaling. Using a variety of methods the authors demonstrate that Cd300lb directly recognizes PS, but not other phospholipids, and further show that Cd300lb-mediated efferocytosis is dependent on PS. In agreement with the previous report, 5 Cd300lb was shown to bind TIM1-or TIM4-expressing cells. However, in contrast to the previous study, Murakami et al. 10 demonstrated that the binding of Cd300lb to TIM1-or TIM4-expressing cells is dependent on PS, as binding was increased in the presence of PS liposomes and Cd300lb failed to associate with either TIM1 or TIM4 in the absence of PS. These findings indicate that Cd300lb does not recognize TIM1 or TIM4 directly but interacts with these proteins indirectly, most likely through bound PS-expressing cell fragments.
Importantly, Murakami et al. 10 showed that Cd300lb promotes efferocytosis via its association with DAP12, thereby initiating positive signals that activate the PI3K pathway. Notably, Cd300lb is able to mediate efferocytosis without any other PS receptor present; however, Cd300lb-mediated efferocytosis can be further enhanced through cooperation with TIM1 or TIM4, indicating that Cd300lb likely synergizes with other PS receptors. Unlike most other PS receptors (e.g., BAI1, MerTK), Cd300lb expression is restricted to myeloid cells, suggesting that Cd300lb regulates immune cell responses rather than functioning as a general PS binding receptor. Interestingly, although TIM4 expression is also limited to immune cells, TIM4 does not have any signaling capacity and requires b1 integrins as co-receptors, whereas Cd300lb acts as a signaling molecule that, upon recognition of PS, is able to promote efferocytosis via the DAP12-Syk-PI3K-AKT pathway (Fig. 1) .
The role of Cd300lb in the development of autoimmune diseases and/or resolution of inflammation remains unclear. Although the most recent results clearly showed that Cd300lb positively regulates efferocytosis, its exact function remains to be elucidated. Cd300lb-deficient mice are protected from ischemia/reperfusion injury (IRI). 5 Since blockade of PS exposure on the cell surface by Annexin V is able to improve kidney and liver IRI, it is tempting to speculate that Cd300lb controls IRI via PS recognition. In addition, Cd300lb-deficient mice are resistant to sepsis-induced lethality. 6 The excessive inflammatory responses induced by microbes promote apoptosis of lymphocytes and epithelial cells, suggesting that Cd300lb mediates the pathology of sepsis via the recognition of ACs.
Thus, although the exact function of each of the CD300 family members requires further elucidation, a growing body of evidence suggests that CD300 receptors are emerging as an important Figure 1 . Simplified model for phosphatidylserine receptor-mediated efferocytosis. Apoptotic cells display various 'eat me' signals like phosphatidylserine (PS) on the outer leaflet of the plasma membrane that are recognized directly or indirectly (via bridging molecules such as Gas6) by different phagocytic PS receptors, including BAI1, TAMs, Stabilin1/2, TIM1/4, and CD300 family members, such as human CD300A or mouse Cd300lb and Cd300lf. The CD300 receptor family consists of both activating and inhibitory receptors. Inhibitory receptors, like CD300A, harbor immune-receptor tyrosine-based inhibitory motifs (ITIMs) within their intracellular tail to regulate signaling events. Cd300lf functions as an activating receptor via the PI3K pathway or as an inhibitory receptor, depending on cell type. The activating receptor Cd300lb requires binding to an adaptor protein, such as DAP12, to gain signaling capacity and regulates efferocytosis via the DAP12-Syk-PI3K-AKT pathway. BAI1, brain-specific angiogenesis inhibitor 1; DAP12, DNAX activation protein of 12 kDa; Gas6, growth arrest-specific 6; TAM, Tyro3, Axl, and MerTK receptor tyrosine kinase; TIM1/4, T-cell immunoglobulin and mucin domain containing 1 and 4.
new family of proteins that positively or negatively regulate immune responses.
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